Holen Sie sich die Stockscreener-App
24.10
3.83%
-0.96
Handel nachbörslich:
24.39
0.29
+1.20%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$25.06
Offen:
$25.17
24-Stunden-Volumen:
1.39M
Relative Volume:
0.65
Marktkapitalisierung:
$2.37B
Einnahmen:
$672.72M
Nettoeinkommen (Verlust:
$-575.44M
KGV:
-4.1295
EPS:
-5.8361
Netto-Cashflow:
$-487.00M
1W Leistung:
-1.91%
1M Leistung:
+21.29%
6M Leistung:
-29.51%
1J Leistung:
-31.92%
1-Tages-Spanne:
$23.95
$25.21
1-Wochen-Bereich:
$23.95
$26.19
52-Wochen-Spanne:
$18.29
$42.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
24.10 | 2.46B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
436.59 | 111.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.36 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
805.38 | 51.89B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.43 | 41.49B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.31 | 35.31B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | Goldman | Buy → Neutral |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx (RARE) CEO gets new RSUs, options and shifts 400K shares - Stock Titan
Ultragenyx (RARE) awards RSUs and 79,936 stock options to officer - Stock Titan
Ultragenyx (RARE) awards RSUs and stock options to executive Pinion - Stock Titan
Ultragenyx (RARE) grants EVP 28,895 RSUs and 49,960 options - Stock Titan
Ultragenyx (RARE) EVP Harris receives RSU and option grants in equity award - Stock Titan
Ultragenyx (RARE) CMO receives 34,674 RSUs and 59,952 stock options - Stock Titan
Ultragenyx (RARE) CFO granted 34,674 RSUs and 59,952 options in equity awards - Stock Titan
Ultragenyx Pharmaceutical stock (US74930A1043): Does its rare disease focus deliver the growth U.S. - AD HOC NEWS
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Osteogenesis Imperfecta Market to Expand Significantly by 2034 with Advancements in Novel Therapies and Rising Disease Awareness, Reports DelveInsight - Barchart.com
Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight - Barchart.com
Massachusetts Financial Services Co. MA Has $7.13 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Free cash flow per share of Ultragenyx Pharmaceutical, Inc. – BIVA:RARE - TradingView — Track All Markets
RARE Maintained by Morgan Stanley -- Price Target Raised to $67 - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
Bear Alert: What are the future prospects of Ultragenyx Pharmaceutical IncWeekly Earnings Recap & Safe Capital Growth Tips - baoquankhu1.vn
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN
Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts (NASDAQ:RARE) - Seeking Alpha
Ultragenyx Pharmaceutical Inc. $RARE Stock Position Cut by SG Americas Securities LLC - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. Shares - National Today
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Ultragenyx Pharmaceutical stock (US74930A1043): Is its rare disease pipeline strong enough to unlock - AD HOC NEWS
Is Ultragenyx Pharmaceutical (RARE) Pricing Reflect Its Long Term Potential After 5 Year Slump - Yahoo Finance
FDA Accepts Ultragenyx’s New BLA Submission for MPS IIIA Gene Therapy UX111 - CGTLive®
FDA Accepts Ultragenyx's Resubmitted BLA for MPS IIIA Gene Therapy UX111 - NeurologyLive
Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares - MarketBeat
RARE DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class ActionRARE - ACCESS Newswire
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors ... - Bluefield Daily Telegraph
Ultragenyx Pharmaceutical Inc. Class Action: Levi & - GlobeNewswire
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome - The Globe and Mail
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm - GlobeNewswire Inc.
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - 巴士的報
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - Finansavisen
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026RARE - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
Ultragenyx (RARE) shares positive results from DTX301 phase 3 study - MSN
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - Finansavisen
Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE - marketbeat.com
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Lelezard
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
RARE Deadline: RARE Investors with Losses in Excess of $100K Hav - GuruFocus
Ultragenyx says gene therapy accepted for FDA review again - MSN
Ultragenyx EVP Pinion sells $228k in shares - Investing.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Ultragenyx Faces Lawsuit Deadline for Investor Losses - National Today
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):